

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Targeting the &ldquo;PVR&ndash;TIGIT axis&rdquo;... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-354/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-354" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Targeting the “PVR–TIGIT axis” with immune checkpoint therapies" />
    
            <meta name="og:title" content="F1000Research Article: Targeting the &ldquo;PVR&ndash;TIGIT axis&rdquo; with immune checkpoint therapies.">
            <meta name="og:description" content="Read the latest article version by Laurent Gorvel, Daniel Olive, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="25255">
            <meta name="article-id" content="22877">
            <meta name="dc.title" content="Targeting the &ldquo;PVR&ndash;TIGIT axis&rdquo; with immune checkpoint therapies">
            <meta name="dc.description" content="Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by the immune infiltrate, the expression of target molecules, and the influence of the tumor microenvironment. It is therefore critical to identify checkpoint antigens that represent alternative targets for immunotherapies. PVR-like molecules play regulatory roles in immune cell functions. These proteins are expressed by different cell types and have been shown to be upregulated in various malignancies. PVR and Nectin-2 are expressed by tumor cells as well as myeloid cells, while TIGIT, CD96, and DNAM-1 are expressed on effector lymphoid cells. PVR is able to bind DNAM-1, CD96, and TIGIT, which results in two distinct profiles of effector cell activation. Indeed, while binding to DNAM-1 induces the release of cytokines and cytotoxicity of cytotoxic effector cells, binding TIGIT induces an immunosuppressive and non-cytotoxic profile. PVR is also able to bind CD96, which induces an immunosuppressive response in murine models. Unfortunately, in humans, results remain contradictory, and this interaction might induce the activation or the suppression of the immune response. Similarly, Nectin-2 was shown to bind TIGIT and to induce regulatory profiles in effectors cells such as NK and T cells. Therefore, these data highlight the potential of each of the molecules of the &ldquo;PVR&ndash;TIGIT axis&rdquo; as a potential target for immune checkpoint therapy. However, many questions remain to be answered to fully understand the mechanisms of this synapse, in particular for human CD96 and Nectin-2, which are still understudied. Here, we review the recent advances in &ldquo;PVR&ndash;TIGIT axis&rdquo; research and discuss the potential of targeting this axis by checkpoint immunotherapies.">
            <meta name="dc.subject" content="PVR, Nectin2, DNAM-1, TIGIT, CD96, Immune checkpoint therapy">
            <meta name="dc.creator" content="Gorvel, Laurent">
            <meta name="dc.creator" content="Olive, Daniel">
            <meta name="dc.date" content="2020/05/13">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.22877.1">
            <meta name="dc.source" content="F1000Research 2020 9:354">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="PVR">
            <meta name="prism.keyword" content="Nectin2">
            <meta name="prism.keyword" content="DNAM-1">
            <meta name="prism.keyword" content="TIGIT">
            <meta name="prism.keyword" content="CD96">
            <meta name="prism.keyword" content="Immune checkpoint therapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/05/13">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="354">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.22877.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-354">
            <meta name="citation_title" content="Targeting the &ldquo;PVR&ndash;TIGIT axis&rdquo; with immune checkpoint therapies">
            <meta name="citation_abstract" content="Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by the immune infiltrate, the expression of target molecules, and the influence of the tumor microenvironment. It is therefore critical to identify checkpoint antigens that represent alternative targets for immunotherapies. PVR-like molecules play regulatory roles in immune cell functions. These proteins are expressed by different cell types and have been shown to be upregulated in various malignancies. PVR and Nectin-2 are expressed by tumor cells as well as myeloid cells, while TIGIT, CD96, and DNAM-1 are expressed on effector lymphoid cells. PVR is able to bind DNAM-1, CD96, and TIGIT, which results in two distinct profiles of effector cell activation. Indeed, while binding to DNAM-1 induces the release of cytokines and cytotoxicity of cytotoxic effector cells, binding TIGIT induces an immunosuppressive and non-cytotoxic profile. PVR is also able to bind CD96, which induces an immunosuppressive response in murine models. Unfortunately, in humans, results remain contradictory, and this interaction might induce the activation or the suppression of the immune response. Similarly, Nectin-2 was shown to bind TIGIT and to induce regulatory profiles in effectors cells such as NK and T cells. Therefore, these data highlight the potential of each of the molecules of the &ldquo;PVR&ndash;TIGIT axis&rdquo; as a potential target for immune checkpoint therapy. However, many questions remain to be answered to fully understand the mechanisms of this synapse, in particular for human CD96 and Nectin-2, which are still understudied. Here, we review the recent advances in &ldquo;PVR&ndash;TIGIT axis&rdquo; research and discuss the potential of targeting this axis by checkpoint immunotherapies.">
            <meta name="citation_description" content="Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by the immune infiltrate, the expression of target molecules, and the influence of the tumor microenvironment. It is therefore critical to identify checkpoint antigens that represent alternative targets for immunotherapies. PVR-like molecules play regulatory roles in immune cell functions. These proteins are expressed by different cell types and have been shown to be upregulated in various malignancies. PVR and Nectin-2 are expressed by tumor cells as well as myeloid cells, while TIGIT, CD96, and DNAM-1 are expressed on effector lymphoid cells. PVR is able to bind DNAM-1, CD96, and TIGIT, which results in two distinct profiles of effector cell activation. Indeed, while binding to DNAM-1 induces the release of cytokines and cytotoxicity of cytotoxic effector cells, binding TIGIT induces an immunosuppressive and non-cytotoxic profile. PVR is also able to bind CD96, which induces an immunosuppressive response in murine models. Unfortunately, in humans, results remain contradictory, and this interaction might induce the activation or the suppression of the immune response. Similarly, Nectin-2 was shown to bind TIGIT and to induce regulatory profiles in effectors cells such as NK and T cells. Therefore, these data highlight the potential of each of the molecules of the &ldquo;PVR&ndash;TIGIT axis&rdquo; as a potential target for immune checkpoint therapy. However, many questions remain to be answered to fully understand the mechanisms of this synapse, in particular for human CD96 and Nectin-2, which are still understudied. Here, we review the recent advances in &ldquo;PVR&ndash;TIGIT axis&rdquo; research and discuss the potential of targeting this axis by checkpoint immunotherapies.">
            <meta name="citation_keywords" content="PVR, Nectin2, DNAM-1, TIGIT, CD96, Immune checkpoint therapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Laurent Gorvel">
            <meta name="citation_author_institution" content="Cancer Research Center of Marseille, INSERM U1068, CNRS U7258, Aix Marseille Universit&eacute;, Institut Paoli &ndash; Calmettes, Marseille, France">
            <meta name="citation_author" content="Daniel Olive">
            <meta name="citation_author_institution" content="Cancer Research Center of Marseille, INSERM U1068, CNRS U7258, Aix Marseille Universit&eacute;, Institut Paoli &ndash; Calmettes, Marseille, France">
            <meta name="citation_publication_date" content="2020/05/13">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="354">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.22877.1">
            <meta name="citation_firstpage" content="354">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-354/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-354.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=25255 /> <input type=hidden id=articleId name=articleId value=22877 /> <input type=hidden id=xmlUrl value="/articles/9-354/v1/xml"/> <input type=hidden id=xmlFileName value="-9-354-v1.xml"> <input type=hidden id=article_uuid value=0858c6f9-8000-4737-bc9f-3840373f77a6 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Targeting the “PVR–TIGIT axis” with immune checkpoint therapies"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.22877.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.22877.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-354"
  },
  "headline": "Targeting the “PVR–TIGIT axis” with immune checkpoint therapies",
  "datePublished": "2020-05-13T12:03:04",
  "dateModified": "2020-05-13T12:03:04",
  "author": [
    {
      "@type": "Person",
      "name": "Laurent Gorvel"
    },    {
      "@type": "Person",
      "name": "Daniel Olive"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by the immune infiltrate, the expression of target molecules, and the influence of the tumor microenvironment. It is therefore critical to identify checkpoint antigens that represent alternative targets for immunotherapies. PVR-like molecules play regulatory roles in immune cell functions. These proteins are expressed by different cell types and have been shown to be upregulated in various malignancies. PVR and Nectin-2 are expressed by tumor cells as well as myeloid cells, while TIGIT, CD96, and DNAM-1 are expressed on effector lymphoid cells. PVR is able to bind DNAM-1, CD96, and TIGIT, which results in two distinct profiles of effector cell activation. Indeed, while binding to DNAM-1 induces the release of cytokines and cytotoxicity of cytotoxic effector cells, binding TIGIT induces an immunosuppressive and non-cytotoxic profile. PVR is also able to bind CD96, which induces an immunosuppressive response in murine models. Unfortunately, in humans, results remain contradictory, and this interaction might induce the activation or the suppression of the immune response. Similarly, Nectin-2 was shown to bind TIGIT and to induce regulatory profiles in effectors cells such as NK and T cells. Therefore, these data highlight the potential of each of the molecules of the &ldquo;PVR&ndash;TIGIT axis&rdquo; as a potential target for immune checkpoint therapy. However, many questions remain to be answered to fully understand the mechanisms of this synapse, in particular for human CD96 and Nectin-2, which are still understudied. Here, we review the recent advances in &ldquo;PVR&ndash;TIGIT axis&rdquo; research and discuss the potential of targeting this axis by checkpoint immunotherapies."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-354/v1",
            "name": "Targeting the “PVR–TIGIT axis” with immune checkpoint therapies"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Targeting the “PVR–TIGIT axis” with immune checkpoint therapies </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=25255 data-id=22877 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22877.1" data-recommended="" data-doi="10.12688/f1000research.22877.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-354/v1/pdf?article_uuid=0858c6f9-8000-4737-bc9f-3840373f77a6" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-22877-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-22877-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-22877-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Gorvel L and Olive D. Targeting the “PVR–TIGIT axis” with immune checkpoint therapies [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):354 (<a class=new-orange href="https://doi.org/10.12688/f1000research.22877.1" target=_blank>https://doi.org/10.12688/f1000research.22877.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-22877-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=22877 id=track-article-signin-22877 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22877?target=/articles/9-354/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=25255 /> <input name=articleId type=hidden value=22877 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Targeting the “PVR–TIGIT axis” with immune checkpoint therapies</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:laurent.gorvel@inserm.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Laurent Gorvel</span></a><a href="https://orcid.org/0000-0001-7526-261X" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7526-261X</div>,&nbsp;</span><span class=""><a href="mailto:daniel.olive@inserm.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Daniel Olive</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:laurent.gorvel@inserm.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Laurent Gorvel</span></a><a href="http://orcid.org/0000-0001-7526-261X" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-7526-261X</div>,&nbsp;</span><span class=""><a href="mailto:daniel.olive@inserm.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Daniel Olive</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 13 May 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.22877.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Cancer Research Center of Marseille, INSERM U1068, CNRS U7258, Aix Marseille Universit&eacute;, Institut Paoli &ndash; Calmettes, Marseille, France<br/> <p> <div class=margin-bottom> Laurent Gorvel <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Daniel Olive <br/> <span>Roles: </span> Funding Acquisition, Resources, Supervision, Validation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=67318-63205></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=67317-63206></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4, anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while these therapies are very efficient in certain tumors, they remain poorly efficient in others. This might be explained by the immune infiltrate, the expression of target molecules, and the influence of the tumor microenvironment. It is therefore critical to identify checkpoint antigens that represent alternative targets for immunotherapies. PVR-like molecules play regulatory roles in immune cell functions. These proteins are expressed by different cell types and have been shown to be upregulated in various malignancies. PVR and Nectin-2 are expressed by tumor cells as well as myeloid cells, while TIGIT, CD96, and DNAM-1 are expressed on effector lymphoid cells. PVR is able to bind DNAM-1, CD96, and TIGIT, which results in two distinct profiles of effector cell activation. Indeed, while binding to DNAM-1 induces the release of cytokines and cytotoxicity of cytotoxic effector cells, binding TIGIT induces an immunosuppressive and non-cytotoxic profile. PVR is also able to bind CD96, which induces an immunosuppressive response in murine models. Unfortunately, in humans, results remain contradictory, and this interaction might induce the activation or the suppression of the immune response. Similarly, Nectin-2 was shown to bind TIGIT and to induce regulatory profiles in effectors cells such as NK and T cells. Therefore, these data highlight the potential of each of the molecules of the “PVR–TIGIT axis” as a potential target for immune checkpoint therapy. However, many questions remain to be answered to fully understand the mechanisms of this synapse, in particular for human CD96 and Nectin-2, which are still understudied. Here, we review the recent advances in “PVR–TIGIT axis” research and discuss the potential of targeting this axis by checkpoint immunotherapies. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> PVR, Nectin2, DNAM-1, TIGIT, CD96, Immune checkpoint therapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Laurent Gorvel (<a href="mailto:laurent.gorvel@inserm.fr">laurent.gorvel@inserm.fr</a>) <br> Daniel Olive (<a href="mailto:daniel.olive@inserm.fr">daniel.olive@inserm.fr</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Laurent Gorvel, Daniel Olive </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> LG is supported by an Asylum Research Centre (ARC) foundation experienced post-doc/young researcher fellowship (Aides individuelles – session de printemps 2018- Post-doctorat en France). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Gorvel L and Olive D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Gorvel L and Olive D. Targeting the “PVR–TIGIT axis” with immune checkpoint therapies [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):354 (<a href="https://doi.org/10.12688/f1000research.22877.1" target=_blank>https://doi.org/10.12688/f1000research.22877.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 13 May 2020, <b>9</b>(F1000 Faculty Rev):354 (<a href="https://doi.org/10.12688/f1000research.22877.1" target=_blank>https://doi.org/10.12688/f1000research.22877.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 13 May 2020, <b>9</b>(F1000 Faculty Rev):354 (<a href="https://doi.org/10.12688/f1000research.22877.1" target=_blank>https://doi.org/10.12688/f1000research.22877.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d12713e142>Introduction</h2><p class="" id=d12713e145>Methods to stimulate the immune system and target malignant cells have evolved over several decades. Indeed, numerous studies showed that patients can develop immune responses against tumor antigens, although clinical benefits remained weak. The reasons for this rely on factors such as the immunogenicity of the target antigen and the tumor microenvironment. On the one hand, target antigens play a critical part in the immunogenicity of a vaccine. On the other hand, the tumor microenvironment has repeatedly been shown to interfere with immune cell function. T cell checkpoint inhibitors have become an effective way to treat cancers. Indeed, antagonistic antibodies, like anti-CTLA-4, are now used as therapies in several cancers and led the way for the targeting of similar immunoregulatory molecules such as programmed cell death (PD-)1 and PD ligand-1 (PDL-1). Anti-PD1 and PDL-1 antibodies are now approved by the US Food and Drug Administration to be used as therapeutic agents<sup><a href="#ref-1">1</a></sup>. However, they are efficient in some cancer types and remain inefficient in others. It is therefore critical to identify checkpoint antigens that represent alternative and/or better targets for immunotherapies.</p><p class="" id=d12713e152>The poliovirus receptor (PVR)-like molecules are a group of the immunoglobulin superfamily that play regulatory roles in T cell and NK cell functions. PVR-like molecules share PVR-signature motifs in the first immunoglobulin variable-like domain and are originally known to mediate epithelial cell–cell contact. PVR (also known as CD155 or Necl-5) and Nectin-2 (also known as Pvrl2 or CD112) are two major ligands that are expressed on epithelial and myeloid cells of the tumor (Human Cell Atlas,<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>). PVR is an integral membrane protein that binds poliovirus and is of interest because it is upregulated during the response to DNA damage, a process that occurs in viral infections and cancers. PVR is able to bind CD226, DNAX accessory molecule-1 (DNAM-1), T Cell-Activated Increased Late Expression Protein, TACTILE (CD96), and T Cell Immunoreceptor with Ig and ITIM domains (TIGIT), which results in a very distinct profile of effector lymphoid cell activation. While binding to DNAM-1 induces the release of pro-inflammatory cytokines and cytotoxicity of T cells and NK cells, binding TIGIT induces a rather anti-inflammatory, non-proliferative, and non-cytotoxic profile<sup><a href="#ref-4">4</a>–<a href="#ref-6">6</a></sup>. Similarly, Nectin-2, an adhesion protein, was shown to bind TIGIT and to induce regulatory profiles in effector cells such as NK and T cells (<a href="#f1">Figure 1</a>). A recent study by Stamm <i>et al.</i> showed that the use of an anti-PVR or anti-TIGIT monoclonal antibody (mAb) resulted in increased lysis of breast cancer cell lines by cytokine-induced killer cells<sup><a href="#ref-7">7</a></sup>. Therefore, PVR, TIGIT, and CD96 also represent interesting targets for immunotherapies because of their expression on the lymphoid effector cells and their immunoregulatory function and involvement in various cancers<sup><a href="#ref-3">3</a>,<a href="#ref-8">8</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/25255/ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure1.gif"><img alt="ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/25255/ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure1.gif"></a><div class=caption><h3>Figure 1. The PVR–TIGIT axis.</h3><p id=d12713e197>PVR and Nectin-2 are expressed on APCs or tumor cells. TIGIT, CD96, and DNAM-1 are expressed on cytotoxic effector cells (CD8<sup>+</sup> T cells and NK cells). PVR affinity for TIGIT is higher than its affinity for CD96 or DNAM-1. Thus, the signaling of the PVR–TIGIT synapse induces immunosuppression rather than effector cell activation and/or cytotoxicity. Signaling through PVR induces anti-inflammatory profiles in dendritic cells and macrophages. CD96 signaling induces immunosuppression in murine models, which was not demonstrated in human models. Similar to PVR, Nectin-2 binds PVR, CD96, or DNAM-1 but with a lower affinity than PVR. APC, antigen-presenting cell; DNAM-1, DNAX accessory molecule-1; NK, natural killer; PVR, poliovirus receptor; TIGIT, T Cell Immunoreceptor with Ig and ITIM domains.</p></div></div><p class="" id=d12713e207>Here we will review the recent advances in PVR–TIGIT axis research and discuss the potential of targeting this axis with immunotherapies. First, we will discuss the expression and function of PVR and Nectin-2 in the modulation of the immune system. Second, we will discuss the expression and function of TIGIT, DNAM-1, and CD96 on lymphoid effector cells as well as tumor cells. Altogether, the aim of this review is to give a comprehensive overview of the interactions between the players of the “PVR–TIGIT synapse” and assess their potential as immunotherapy targets.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12713e213>Function of PVR and Nectin-2 in the regulation of the immune response</h2><div class=section><a name=d12713e216 class=n-a></a><h3 class=section-title>PVR as a relevant new target for immunotherapy</h3><p class="" id=d12713e221>PVR (CD155) was shown to be the poliovirus’s point of entry into cells, hence its name. It is a cell adhesion molecule that allows adhesion and/or migration following a gradient of chemoattractant<sup><a href="#ref-9">9</a></sup>. Indeed, staining demonstrated that PVR accumulates at the edges of lamellipods, pseudopods, or dendrites<sup><a href="#ref-9">9</a></sup>. PVR expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma, as it correlated with tumor migration, development of metastases, tissue and lymph node invasion, relapse, and poorer survival<sup><a href="#ref-10">10</a>–<a href="#ref-15">15</a></sup>. PVR was demonstrated to be upregulated upon DNA damage after signaling through the Sonic hedgehog pathway or after stimulation of the RAS and TLR4 pathways. This is relevant for cancer therapy, as chemotherapy might induce the expression of PVR and therefore either improve immune response or increase immunosuppression<sup><a href="#ref-9">9</a>,<a href="#ref-16">16</a></sup>. This comes from the fact that PVR binds to three different molecules, which leads to very different outcomes. Indeed, PVR might bind to DNAM-1 (which is expressed on NK cells and cytotoxic CD8<sup>+</sup> T cells) and deliver a positive signal, leading to an anti-tumoral response (see DNAM-1 section). However, PVR preferentially binds TIGIT, for which it has more affinity, and therefore tends to induce an immunosuppressive profile of TIGIT-expressing cells. PVR was also described to bind CD96, whose function remains elusive in humans (see CD96 section). Interestingly, the reverse signal following PVR binding to DNAM-1 or TIGIT was not extensively studied, and only a few studies demonstrated that this signal through PVR influences the polarization of macrophages toward an anti-inflammatory M2-like profile<sup><a href="#ref-17">17</a></sup>. Similarly, the signaling through PVR in dendritic cells induced a rather tolerogenic profile. Indeed, the use of recombinant human TIGIT-fc fragments allowed mature dendritic cells to produce IL-10 and regulated the expression of activation markers such as CD80 and CD86<sup><a href="#ref-18">18</a></sup> (<a href="#f2">Figure 2, A</a>). This immunosuppressive effect might be due to the presence of an ITIM motif in the isoform of PVR. Noteworthily, PVR exists in four different isoforms: α and δ are transmembrane, and δ lacks the ITIM motif, and β and γ are soluble isoforms that lack the transmembrane domains<sup><a href="#ref-9">9</a></sup>. We can hypothesize that this effect is a negative feedback signal on antigen-presenting cells to avoid unnecessary inflammation.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/25255/ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure2.gif"><img alt="ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/25255/ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure2.gif"></a><div class=caption><h3>Figure 2. PVR’s role in immunomodulation.</h3><p id=d12713e275><b>A</b>. Classical role of PVR in synapse signaling, tweaking the immune response toward a pro-tumoral profile. <b>B</b>. Using an antagonistic mAb directed against PVR would block its interaction with TIGIT, CD96, and DNAM-1. This would partially inhibit the signaling pathway, as the synapse would be maintained by Nectin-2 but with a much weaker affinity. Upon blockade, DNAM-1 expression would be upregulated in effector cells. APC, antigen-presenting cell; DNAM-1, DNAX accessory molecule-1; mAb, monoclonal antibody; NK, natural killer; PVR, poliovirus receptor; TIGIT, T Cell Immunoreceptor with Ig and ITIM domains.</p></div></div><p class="" id=d12713e287>However, in the case of cancer, such negative signaling is of interest, and the idea of blocking PVR becomes attractive. Indeed, blocking PVR would result in blocking three ligands (TIGIT, DNAM-1, and CD96). Considering that PVR has a better affinity for the immunosuppressive TIGIT, this could be enough to reverse immunosuppression. This would also allow the interaction of DNAM-1 with its other ligand Nectin-2 and promote an anti-tumoral response. However, TIGIT is also able to bind Nectin-2 and could still maintain immunosuppression (see Nectin-2 section). Interestingly, PVR blockade might be beneficial for the expression of DNAM-1, as studies demonstrated that the expression of PVR downregulates that of DNAM-1 and that blocking PVR would result in increased levels of DNAM-1<sup><a href="#ref-9">9</a>,<a href="#ref-19">19</a></sup>. In support of a PVR blockade strategy, studies in acute myeloid leukemia (AML) and melanoma cell lines as well as <i>in vivo</i> murine tumor models resulted, respectively, in the activation of anti-tumoral cell types and avoidance of metastases (<a href="#f2">Figure 2, B</a>). Noteworthily, clinical trials targeting PVR and its interactions are either antibodies directed against TIGIT in combination with other mAbs or chemotherapy or radiation (refer to TIGIT section) or use PVR as a point of entry for recombinant oncolytic polioviruses in the case of advanced gliomas (NCT01491893, NCT03043391, and NCT02986178) or triple negative breast cancer (NCT03564782)<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d12713e307>Altogether, PVR represents a potential immunotherapy target thanks to its role as a keystone of the PVR–TIGIT immunosuppressive synapse.</p></div><div class=section><a name=d12713e311 class=n-a></a><h3 class=section-title>Is Nectin-2 a good target for immunotherapies?</h3><p class="" id=d12713e316>Nectins are cell adhesion molecules which are involved in various developmental processes including but not limited to ear development, spermatogenesis, myelination, and axon guidance<sup><a href="#ref-20">20</a></sup>. They also were described to be involved in neurodegenerative diseases such as Alzheimer’s disease, viral infections, and cancers. Nectin-2 was shown to be expressed in breast and ovarian tumors<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. Recently, their involvement in immune response modulation was proved, as they were part of the PVR-like signaling pathway. More specifically, Nectin-2 (PRR2, PVRL2, and CD112), a protein expressed by primary tumor cells, cell lines, and to a lesser extent on immune cells such as monocytes, macrophages, B cells, and dendritic cells, was shown to interact with DNAM-1 and/or TIGIT to alter the immune response (Human Cell Atlas,<sup><a href="#ref-9">9</a>,<a href="#ref-13">13</a></sup>). Indeed, similar to PVR, Nectin-2 is able to bind DNAM-1 on CD8<sup>+</sup> T cells and NK cells, leading to an anti-tumoral response, or TIGIT, leading to a pro-tumoral response via the inhibition of cytotoxicity. However, while PVR binds with a strong affinity to TIGIT, Nectin-2 affinity to TIGIT is much weaker. Considering this redundancy with PVR function in the modulation of the immune response, Nectin-2 could be an interesting target for immunotherapy as well. Indeed, using antagonistic mAbs to block Nectin-2 interaction with TIGIT could represent an alternative in the cases where PVR is weakly expressed. Furthermore, no reverse signaling through Nectin-2 has been demonstrated to date and therefore would not affect a potential beneficial response induced by Nectin-2 binding to its ligands. Interestingly, Nectin-2 was shown to bind PVR Related Immunoglobulin Domain Containing (PVRIG), another inhibitory receptor of the nectin family. The blockade of PVRIG using a mAb resulted in increased production of cytokines and cytotoxicity of CD8<sup>+</sup> T cells, which was not the case after TIGIT blockade<sup><a href="#ref-22">22</a></sup>. This highlighted that Nectin-2 inhibition was mainly dependent on its binding to PVRIG. To our knowledge, no clinical trials involving the targeting of Nectin-2 are currently ongoing.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12713e352>TIGIT, DNAM-1, and CD96 function in effector cells</h2><div class=section><a name=d12713e355 class=n-a></a><h3 class=section-title>The good: DNAM-1</h3><p class="" id=d12713e360>DNAM-1 is expressed by a highly diverse set of immune cells, which includes T cells (CD8<sup>+</sup> and CD4<sup>+</sup>), NK cells, B cells, and monocytes. Its function has been studied intensively in NK cells and CD8<sup>+</sup> T cells, where its activation leads to the activation of these cytotoxic cells as well as their degranulation and therefore stimulates their anti-tumoral response<sup><a href="#ref-23">23</a>,<a href="#ref-24">24</a></sup>. Therefore, it is not surprising to find that DNAM-1 expression is downregulated in various types of tumors including ovarian and breast cancer<sup><a href="#ref-14">14</a>,<a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>. DNAM-1’s strong activation functions allowed the development of a rationale to target or use this molecule in the treatment of malignancies. Indeed, ideas of using DNAM-1<sup>+</sup> cytokine-induced killer cells or developing DNAM-1 chimeric antigen receptor (CAR) T cells have emerged<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. Creating autologous T cells which are positive for DNAM-1 would increase their efficiency and specificity in the case of PVR<sup>+</sup> and Nectin-2<sup>+</sup> tumors. Interestingly, no clinical trials are currently ongoing with agonistic mAbs directed against DNAM-1 to stimulate CD8<sup>+</sup> T cells and NK cells, which is probably because of the broad expression of DNAM-1 among immune cells and therefore the increasing chance of observing adverse effects.</p></div><div class=section><a name=d12713e410 class=n-a></a><h3 class=section-title>The bad: TIGIT, a rising star in immune checkpoint targeting</h3><p class="" id=d12713e415>The number of studies focusing on TIGIT has increased over the past few years and allowed researchers to form a catalog of TIGIT expression in tumors. Indeed, TIGIT was found to be expressed on the lymphoid cells in non-small cell lung carcinoma (NSCLC), melanoma, breast cancer, colon adenocarcinoma (COAD), AML, and multiple myeloma (MM)<sup><a href="#ref-4">4</a>,<a href="#ref-29">29</a>–<a href="#ref-32">32</a></sup>. TIGIT is an inhibitory immunoglobulin receptor which possesses a tyrosine-based inhibitory motif domain (ITIM). It is expressed by CD8<sup>+</sup>, CD4<sup>+</sup> T cells (mainly regulatory T cells [Tregs]), and NK cells<sup><a href="#ref-18">18</a>,<a href="#ref-33">33</a></sup>. It represents the immunosuppressive signaling counterpart of DNAM-1, with which it competes for the ligation of Nectin-2 and PVR. However, TIGIT was described to present more binding affinity for PVR than DNAM-1, which means that the expression of TIGIT on tumor-infiltrating lymphocytes is powerful enough to skew the immune response toward an immunosuppressed phenotype and therefore abrogates NK cell and CD8<sup>+</sup> T cell cytotoxicity<sup><a href="#ref-33">33</a></sup>. Furthermore, TIGIT signaling was also described to prevent the homodimerization of DNAM-1, therefore avoiding its signaling and the subsequent antitumoral response. TIGIT was also associated with PD-1 expression, among a 15-gene signature which was related to T cell exhaustion<sup><a href="#ref-5">5</a>,<a href="#ref-34">34</a></sup>. Interestingly, TIGIT is expressed on a Treg subset, which is surprising considering that signaling through TIGIT usually inhibits the function of the cell type it is expressed on. Therefore, Tregs which express TIGIT could be less immunosuppressive. A response was given by Bottino <i>et al.</i> that described the functional role of TIGIT<sup>+</sup> Tregs compared to their negative counterpart. They demonstrated that TIGIT<sup>+</sup> Tregs skewed the CD4<sup>+</sup> T cell response toward a Th2 profile, therefore suppressing the function of Th1 inflammatory cell types<sup><a href="#ref-35">35</a></sup>. In addition, <i>in vivo</i>, TIGIT activation led to the suppression of CD8<sup>+</sup> T cell cytotoxicity via the production of IL-10 (<a href="#f3">Figure 3</a>).</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/25255/ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure3.gif"><img alt="ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/25255/ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure3.gif"></a><div class=caption><h3>Figure 3. TIGIT immunosuppressive function.</h3><p id=d12713e492>TIGIT binds to its ligand, which induces the production of IL-10 and TGF-β by Tregs. This induces the polarization of T cells toward a Th2 profile, thus avoiding inflammation. IL-10 will create an anti-inflammatory microenvironment, which participates in the inhibition of CD8<sup>+</sup> T cell cytotoxicity. The binding of TIGIT by its ligands induces a loss of cytotoxicity, immunosuppression, and exhaustion on effector cytotoxic cells. Signaling through TIGIT also blocks DNAM-1 dimerization, which leads to decreased DNAM-1 expression on effector cells. APC, antigen-presenting cell; DNAM-1, DNAX accessory molecule-1; IL, interleukin; PVR, poliovirus receptor; TGF, transforming growth factor; TIGIT, T Cell Immunoreceptor with Ig and ITIM domains; Th2, T helper type 2; Treg, regulatory T cell.</p></div></div><p class="" id=d12713e502>Taken together, these findings highlight the powerful immunosuppressive functions of TIGIT. Indeed, the expression of TIGIT on cytotoxic cells prevents their activation and degranulation by competition with DNAM-1, while its expression on Tregs allows the suppression of other inflammatory cell types via the regulation of anti-inflammatory cytokines. This is why targeting TIGIT with antagonistic mAbs appears to be a logical strategy. So far, six clinical trials using anti-TIGIT antibodies are ongoing. Oncomed Pharmaceutical’s anti-TIGIT mAb etigilimab (OMP-313M32) underwent safety and pharmacodynamics testing in a phase I dose escalation study (NCT031119428) alone or in combination with anti-PD1 (nivolumab) in an attempt to treat advanced solid tumors. Etigilimab seemed to be well tolerated by patients after phase Ia; however, this trial was stopped in phase Ib for sponsor reasons. Other phase I and II clinical trials are still ongoing: tiragolumab (Genentech Roche) for the treatment of NSCLC, AB154 (Arcus Biosciences) for the treatment of advanced solid malignancies, MK-7684 (Merck) for the treatment of solid tumors, BMS986207 (Bristol Myers Squibb) for the treatment of advanced and metastatic solid tumors, and ASP8374 (Astellas Pharma, Potenza Therapeutics) for the treatment of advanced or metastatic solid malignancies (reviewed in <a href="#ref-29">29</a>).</p></div><div class=section><a name=d12713e509 class=n-a></a><h3 class=section-title>The ugly: the role for human CD96 in immune response modulation is poorly understood</h3><p class="" id=d12713e514>CD96 was first described as a marker of T cells (TACTILE); however, besides its expression, there was no supporting evidence of a strong functional aspect of CD96 in these cells. CD96 is also expressed on NK cells, in which, in murine models, signaling through CD96 would inhibit inflammatory cytokine production as well as cytotoxicity<sup><a href="#ref-36">36</a></sup>. Still, in murine models, CD96 was proven to possess a direct inhibitory role of anti-tumor function notably in NK cells. Indeed, CD96 inhibits IFN-γ production by NK cells, which would have interacted with mature/activated dendritic cells. In support of this information, anti-mCD96 mAb increased metastasis reduction after tumor resection. However, CD96 in humans exhibits a different profile, and a direct inhibition mechanism through CD96 could not be demonstrated<sup><a href="#ref-14">14</a>,<a href="#ref-37">37</a></sup>. Therefore, multiple hypotheses are being investigated. Among them, one proposition is that the inhibition of an anti-tumoral response is compartmentalized between TIGIT and CD96. In this hypothesis, TIGIT would mainly inhibit CD8<sup>+</sup> T cells while CD96 would inhibit NK cells. However, it was described that the engagement of human CD96 could activate NK cells, notably by inducing adhesion, promoting cytotoxicity and PVR acquisition of target cells<sup><a href="#ref-38">38</a></sup>. This highlights the fact that CD96 signaling might be more complex than just an inhibitory pathway. Following this idea, an investigation of the intracytoplasmic domain of CD96 is necessary to understand its signaling and function. CD96 exhibits a short intra-cytoplasmic tail that may bind to GRB2 depending on the presence or the absence of a YXXM motif<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>. YXXM motifs were shown to bind and activate phosphatidylinositol 3-kinases (PI3Ks) and subsequently the AKT kinase<sup><a href="#ref-41">41</a>–<a href="#ref-43">43</a></sup>. A YXXM motif and downstream signal were shown to regulate growth, proliferation, survival, and immune response regulation. Also, the PI3K pathway was upregulated in most human tumors and found to be involved in cancer cell resistance to anti-tumor therapies<sup><a href="#ref-43">43</a>–<a href="#ref-45">45</a></sup>. Interestingly, a YXXM motif-bearing short cytoplasmic tail was also found in the cases of CD28 as well as ICOS signaling and revealed two outcomes. Indeed, in the case of CD28 signaling, the short cytoplasmic tail binds to GRB2, therefore inducing the production of IL-2. On the contrary, the ICOS short cytoplasmic tail cannot bind GRB2, which stops the signaling and therefore did not lead to IL-2 production. However, the importance of the YXXM motif of human CD96 for signaling and response cannot be assessed owing to its very low specificity<sup><a href="#ref-6">6</a>,<a href="#ref-39">39</a></sup> (<a href="#f4">Figure 4</a>). Finally, it remains possible that the response to stimulation of human CD96 might depend on the cell type that it is expressed on. This means that the use of anti-human CD96 mAbs should be carefully considered and that immunophenotyping should be performed for each patient to determine the expression pattern of CD96.</p><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/25255/ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure4.gif"><img alt="ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/25255/ed2a1715-7dd7-48ff-a6dc-6171e1f28ce8_figure4.gif"></a><div class=caption><h3>Figure 4. Murine and human CD96 signaling and function in NK cells.</h3><p id=d12713e577>Murine CD96 possesses an intracellular ITIM motif, which leads to an inhibitory signal and the abrogation of the inflammatory immune response and cytotoxicity of NK cells. Human CD96 signaling is more complex and poorly studied. 1. The intracellular domain of human CD96 harbors a YXXM motif, which may or may not bind GRB2. GRB2 might lead to the activation or inhibition of NK cells. 2. Human CD96 signaling was shown to induce adhesion, migration, and cytotoxicity in NK cells. GRB2, growth factor receptor-bound protein 2; ITIM, immunoreceptor tyrosine-based inhibition motif; NK, natural killer.</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d12713e588>Concluding remarks</h2><p class="" id=d12713e591>The immunological synapse formed by the interaction of PVR and Nectin-2 with their receptors DNAM-1, TIGIT, and CD96 represents a complex interaction system. These interactions are being increasingly studied by the scientific community, as they are being included in a global effort to understand the dynamics and the function of putative immunotherapy targets. The PVR–TIGIT axis is composed of two main ligands (PVR and Nectin-2), which interact with three receptors (DNAM-1, TIGIT, and CD96). Therefore, designing an approach for targeting any of these molecules with antagonistic mAbs should consider the multiple interactions and alternative binding that may occur and avoid an optimal response. Indeed, blocking TIGIT interactions with its ligands seems obvious considering the inhibitory nature of its signaling. However, one should consider that CD96, as ambiguous as its functions seem to be in humans, might participate in the inhibition of an anti-tumor response. Similarly, as mentioned in the section dedicated to PVR, blocking PVR might not be enough to rescue a fully active anti-tumoral response because Nectin-2 is able to bind TIGIT too and induce an inhibitory signal. PVR is receiving more and more attention as a checkpoint blockade therapy target, mainly for its keystone role in the PVR–TIGIT axis. Indeed, PVR is able to bind both inhibitory and activating receptors of the nectin-like protein family, and studies show that using anti-PVR mAbs to avoid its interactions with inhibitory receptors allows the recovery of the anti-tumoral response<sup><a href="#ref-9">9</a>,<a href="#ref-19">19</a>,<a href="#ref-46">46</a></sup>. This makes PVR an interesting checkpoint blockade target. In addition, PVR is being evaluated in clinical trials as a point of entry for oncolytic polioviruses (see PVR section). DNAM-1 is also being investigated as a target for immunotherapy considering its function in the activation of cytotoxic lymphocytes. Indeed, strategies aimed at stimulating the DNAM-1 pathway are being developed, including the use of agonistic mAbs or DNAM-1-based adoptive cell transfer. Nectin-2 remains poorly studied as a target for immunotherapy, mainly because of its weaker affinity for both DNAM-1 and TIGIT, as well as the absence of retro-signal. However, Nectin-2 still represents a potential target, especially in tumors where its expression is elevated. CD96 could also represent an obvious target for immune checkpoint blockade if its function was as clear in humans as it is in murine models. Indeed, while murine CD96 signaling induces an immunosuppressive signal, it is less clear in humans where CD96 might be an activator or an inhibitor, which might also depend on the cell type they are expressed on. Therefore, more thorough studies on the regulation, signaling, and function of CD96 might be necessary to evaluate the true potential of CD96 as an immune checkpoint therapy target. Nonetheless, the PVR–TIGIT synapse represents a keystone in the regulation of the immune response to the tumoral microenvironment and offers multiple angles of attack to rescue a proper anti-tumoral response.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d12713e608 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d13039>References</h2><div class="section ref-list"><a name=d12713e608 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732456067"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e615 class=n-a></a>Marin-Acevedo JA, Soyano AE, Dholaria B, <i> et al.</i>: Cancer immunotherapy beyond immune checkpoint inhibitors. <i>J Hematol Oncol.</i> 2018; <b>11</b>(1): 8. <a target=xrefwindow id=d12713e626 href="http://www.ncbi.nlm.nih.gov/pubmed/29329556">PubMed Abstract </a> | <a target=xrefwindow id=d12713e629 href="https://doi.org/10.1186/s13045-017-0552-6">Publisher Full Text </a> | <a target=xrefwindow id=d12713e633 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5767051">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732456067">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d12713e646 class=n-a></a>Gao J, Zheng Q, Xin N, <i> et al.</i>: CD155, an onco-immunologic molecule in human tumors. <i>Cancer Sci.</i> 2017; <b>108</b>(10): 1934–8. <a target=xrefwindow id=d12713e657 href="http://www.ncbi.nlm.nih.gov/pubmed/28730595">PubMed Abstract </a> | <a target=xrefwindow id=d12713e660 href="https://doi.org/10.1111/cas.13324">Publisher Full Text </a> | <a target=xrefwindow id=d12713e664 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5623745">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d12713e673 class=n-a></a>Zhu Y, Paniccia A, Schulick AC, <i> et al.</i>: Identification of CD112R as a novel checkpoint for human T cells. <i>J Exp Med.</i> 2016; <b>213</b>(2): 167–76. <a target=xrefwindow id=d12713e684 href="http://www.ncbi.nlm.nih.gov/pubmed/26755705">PubMed Abstract </a> | <a target=xrefwindow id=d12713e687 href="https://doi.org/10.1084/jem.20150785">Publisher Full Text </a> | <a target=xrefwindow id=d12713e691 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4749091">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d12713e700 class=n-a></a>Chauvin JM, Pagliano O, Fourcade J, <i> et al.</i>: TIGIT and PD-1 impair tumor antigen-specific CD8<sup>+</sup> T cells in melanoma patients. <i>J Clin Invest.</i> 2015; <b>125</b>(5): 2046–58. <a target=xrefwindow id=d12713e714 href="http://www.ncbi.nlm.nih.gov/pubmed/25866972">PubMed Abstract </a> | <a target=xrefwindow id=d12713e718 href="https://doi.org/10.1172/JCI80445">Publisher Full Text </a> | <a target=xrefwindow id=d12713e721 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4463210">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d12713e730 class=n-a></a>Johnston RJ, Comps-Agrar L, Hackney J, <i> et al.</i>: The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8<sup>+</sup> T Cell Effector Function. <i>Cancer Cell.</i> 2014; <b>26</b>(6): 923–37. <a target=xrefwindow id=d12713e744 href="http://www.ncbi.nlm.nih.gov/pubmed/25465800">PubMed Abstract </a> | <a target=xrefwindow id=d12713e748 href="https://doi.org/10.1016/j.ccell.2014.10.018">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d12713e758 class=n-a></a>Dougall WC, Kurtulus S, Smyth MJ, <i> et al.</i>: TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy. <i>Immunol Rev.</i> 2017; <b>276</b>(1): 112–20. <a target=xrefwindow id=d12713e769 href="http://www.ncbi.nlm.nih.gov/pubmed/28258695">PubMed Abstract </a> | <a target=xrefwindow id=d12713e772 href="https://doi.org/10.1111/imr.12518">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736964297"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e781 class=n-a></a>Stamm H, Oliveira-Ferrer L, Grossjohann EM, <i> et al.</i>: Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. <i>Oncoimmunology.</i> 2019; <b>8</b>(12): e1674605. <a target=xrefwindow id=d12713e792 href="http://www.ncbi.nlm.nih.gov/pubmed/31741778">PubMed Abstract </a> | <a target=xrefwindow id=d12713e795 href="https://doi.org/10.1080/2162402X.2019.1674605">Publisher Full Text </a> | <a target=xrefwindow id=d12713e799 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6844319">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736964297">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d12713e812 class=n-a></a>Xu Z, Jin B: A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. <i>Cell Mol Immunol.</i> 2010; <b>7</b>(1): 11–9. <a target=xrefwindow id=d12713e820 href="http://www.ncbi.nlm.nih.gov/pubmed/20081873">PubMed Abstract </a> | <a target=xrefwindow id=d12713e823 href="https://doi.org/10.1038/cmi.2009.108">Publisher Full Text </a> | <a target=xrefwindow id=d12713e826 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4003259">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734144096"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e835 class=n-a></a>Kučan Brlić P, Lenac Roviš T, Cinamon G, <i> et al.</i>: Targeting PVR (CD155) and its receptors in anti-tumor therapy. <i>Cell Mol Immunol.</i> 2019; <b>16</b>(1): 40–52. <a target=xrefwindow id=d12713e846 href="http://www.ncbi.nlm.nih.gov/pubmed/30275538">PubMed Abstract </a> | <a target=xrefwindow id=d12713e849 href="https://doi.org/10.1038/s41423-018-0168-y">Publisher Full Text </a> | <a target=xrefwindow id=d12713e853 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6318332">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734144096">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d12713e866 class=n-a></a>Gromeier M, Solecki D, Patel DD, <i> et al.</i>: Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: Implications for the pathogenesis of poliomyelitis. <i>Virology.</i> 2000; <b>273</b>(2): 248–57. <a target=xrefwindow id=d12713e877 href="http://www.ncbi.nlm.nih.gov/pubmed/10915595">PubMed Abstract </a> | <a target=xrefwindow id=d12713e880 href="https://doi.org/10.1006/viro.2000.0418">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d12713e889 class=n-a></a>Masson D, Jarry A, Baury B, <i> et al.</i>: Overexpression of the <i>CD155</i> gene in human colorectal carcinoma. <i>Gut.</i> 2001; <b>49</b>(2): 236–40. <a target=xrefwindow id=d12713e903 href="http://www.ncbi.nlm.nih.gov/pubmed/11454801">PubMed Abstract </a> | <a target=xrefwindow id=d12713e907 href="https://doi.org/10.1136/gut.49.2.236">Publisher Full Text </a> | <a target=xrefwindow id=d12713e910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1728395">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d12713e920 class=n-a></a>Castriconi R, Dondero A, Corrias MV, <i> et al.</i>: Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. <i>Cancer Res.</i> 2004; <b>64</b>(24): 9180–4. <a target=xrefwindow id=d12713e931 href="http://www.ncbi.nlm.nih.gov/pubmed/15604290">PubMed Abstract </a> | <a target=xrefwindow id=d12713e934 href="https://doi.org/10.1158/0008-5472.CAN-04-2682">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d12713e943 class=n-a></a>Pende D, Bottino C, Castriconi R, <i> et al.</i>: PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: Involvement in tumor cell lysis. <i>Mol Immunol.</i> 2005; <b>42</b>(4): 463–9. <a target=xrefwindow id=d12713e954 href="http://www.ncbi.nlm.nih.gov/pubmed/15607800">PubMed Abstract </a> | <a target=xrefwindow id=d12713e957 href="https://doi.org/10.1016/j.molimm.2004.07.028">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d12713e966 class=n-a></a>Carlsten M, Björkström NK, Norell H, <i> et al.</i>: DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells. <i>Cancer Res.</i> 2007; <b>67</b>(3): 1317–25. <a target=xrefwindow id=d12713e977 href="http://www.ncbi.nlm.nih.gov/pubmed/17283169">PubMed Abstract </a> | <a target=xrefwindow id=d12713e980 href="https://doi.org/10.1158/0008-5472.CAN-06-2264">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736147259"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e989 class=n-a></a>Triki H, Charfi S, Bouzidi L, <i> et al.</i>: CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration. <i>Life Sci.</i> 2019; <b>231</b>: 116543. <a target=xrefwindow id=d12713e1000 href="http://www.ncbi.nlm.nih.gov/pubmed/31176775">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1003 href="https://doi.org/10.1016/j.lfs.2019.116543">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736147259">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737325146"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1016 class=n-a></a>Molfetta R, Zitti B, Lecce M, <i> et al.</i>: CD155: A Multi-Functional Molecule in Tumor Progression. <i>Int J Mol Sci.</i> 2020; <b>21</b>(3): pii: E922. <a target=xrefwindow id=d12713e1027 href="http://www.ncbi.nlm.nih.gov/pubmed/32019260">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1030 href="https://doi.org/10.3390/ijms21030922">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1034 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7037299">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737325146">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d12713e1047 class=n-a></a>Chen X, Lu PH, Liu L, <i> et al.</i>: TIGIT negatively regulates inflammation by altering macrophage phenotype. <i>Immunobiology.</i> 2016; <b>221</b>(1): 48–55. <a target=xrefwindow id=d12713e1058 href="http://www.ncbi.nlm.nih.gov/pubmed/26307002">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1061 href="https://doi.org/10.1016/j.imbio.2015.08.003">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d12713e1071 class=n-a></a>Yu X, Harden K, Gonzalez LC, <i> et al.</i>: The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. <i>Nat Immunol.</i> 2009; <b>10</b>(1): 48–57. <a target=xrefwindow id=d12713e1082 href="http://www.ncbi.nlm.nih.gov/pubmed/19011627">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1085 href="https://doi.org/10.1038/ni.1674">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733853043"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1094 class=n-a></a>Stamm H, Wellbrock J, Fiedler W: Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. <i>Mamm Genome.</i> 2018; <b>29</b>(11–2): 694–702. <a target=xrefwindow id=d12713e1102 href="http://www.ncbi.nlm.nih.gov/pubmed/30132062">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1105 href="https://doi.org/10.1007/s00335-018-9770-7">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733853043">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733362580"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1118 class=n-a></a>Stamm H, Klingler F, Grossjohann EM, <i> et al.</i>: Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. <i>Oncogene.</i> 2018; <b>37</b>(39): 5269–80. <a target=xrefwindow id=d12713e1129 href="http://www.ncbi.nlm.nih.gov/pubmed/29855615">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1132 href="https://doi.org/10.1038/s41388-018-0288-y">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1136 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6160395">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733362580">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d12713e1149 class=n-a></a>Mandai K, Rikitake Y, Mori M, <i> et al.</i>: Nectins and nectin-like molecules in development and disease. <i>Curr Top Dev Biol.</i> 2015; <b>112</b>: 197–231. <a target=xrefwindow id=d12713e1160 href="http://www.ncbi.nlm.nih.gov/pubmed/25733141">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1163 href="https://doi.org/10.1016/bs.ctdb.2014.11.019">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d12713e1172 class=n-a></a>Oshima T, Sato S, Kato J, <i> et al.</i>: Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. <i>Mol Cancer.</i> 2013; <b>12</b>: 60. <a target=xrefwindow id=d12713e1183 href="http://www.ncbi.nlm.nih.gov/pubmed/23758976">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1186 href="https://doi.org/10.1186/1476-4598-12-60">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1190 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3698035">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734885959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1199 class=n-a></a>Whelan S, Ophir E, Kotturi MF, <i> et al.</i>: PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8<sup>+</sup> T-cell Function. <i>Cancer Immunol Res.</i> 2019; <b>7</b>(2): 257–68. <a target=xrefwindow id=d12713e1213 href="http://www.ncbi.nlm.nih.gov/pubmed/30659054">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1217 href="https://doi.org/10.1158/2326-6066.CIR-18-0442">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7001734">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734885959">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d12713e1234 class=n-a></a>Gilfillan S, Chan CJ, Cella M, <i> et al.</i>: DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. <i>J Exp Med.</i> 2008; <b>205</b>(13): 2965–73. <a target=xrefwindow id=d12713e1245 href="http://www.ncbi.nlm.nih.gov/pubmed/19029380">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1248 href="https://doi.org/10.1084/jem.20081752">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1252 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2605240">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d12713e1261 class=n-a></a>Iguchi-Manaka A, Kai H, Yamashita Y, <i> et al.</i>: Accelerated tumor growth in mice deficient in DNAM-1 receptor. <i>J Exp Med.</i> 2008; <b>205</b>(13): 2959–64. <a target=xrefwindow id=d12713e1272 href="http://www.ncbi.nlm.nih.gov/pubmed/19029379">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1275 href="https://doi.org/10.1084/jem.20081611">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1279 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2605241">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d12713e1288 class=n-a></a>Pende D, Castriconi R, Romagnani P, <i> et al.</i>: Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. <i>Blood.</i> 2006; <b>107</b>(5): 2030–6. <a target=xrefwindow id=d12713e1299 href="http://www.ncbi.nlm.nih.gov/pubmed/16304049">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1302 href="https://doi.org/10.1182/blood-2005-07-2696">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d12713e1311 class=n-a></a>Mamessier E, Sylvain A, Bertucci F, <i> et al.</i>: Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. <i>Cancer Res.</i> 2011; <b>71</b>(21): 6621–32. <a target=xrefwindow id=d12713e1322 href="http://www.ncbi.nlm.nih.gov/pubmed/21937679">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1325 href="https://doi.org/10.1158/0008-5472.CAN-11-0792">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d12713e1334 class=n-a></a>Pievani A, Borleri G, Pende D, <i> et al.</i>: Dual-functional capability of CD3<sub>+</sub>CD56<sub>+</sub> CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. <i>Blood.</i> 2011; <b>118</b>(12): 3301–10. <a target=xrefwindow id=d12713e1352 href="http://www.ncbi.nlm.nih.gov/pubmed/21821703">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1355 href="https://doi.org/10.1182/blood-2011-02-336321">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d12713e1364 class=n-a></a>Wu MR, Zhang T, Alcon A, <i> et al.</i>: DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit <i>in vivo</i> efficacy against melanoma. <i>Cancer Immunol Immunother.</i> 2015; <b>64</b>(4): 409–18. <a target=xrefwindow id=d12713e1378 href="http://www.ncbi.nlm.nih.gov/pubmed/25549845">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1382 href="https://doi.org/10.1007/s00262-014-1648-2">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1385 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4370794">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737077158"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1395 class=n-a></a>Harjunpää H, Guillerey C: TIGIT as an emerging immune checkpoint. <i>Clin Exp Immunol.</i> 2020; <b>200</b>(2): 108–119. <a target=xrefwindow id=d12713e1403 href="http://www.ncbi.nlm.nih.gov/pubmed/31828774">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1406 href="https://doi.org/10.1111/cei.13407">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7160651">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737077158">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735573587"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1422 class=n-a></a>Stålhammar G, Seregard S, Grossniklaus HE: Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma. <i>Cancer Med.</i> 2019; <b>8</b>(6): 2784–92. <a target=xrefwindow id=d12713e1430 href="http://www.ncbi.nlm.nih.gov/pubmed/30993893">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1433 href="https://doi.org/10.1002/cam4.2167">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1436 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6558646">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735573587">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735695817"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1449 class=n-a></a>O'Brien SM, Klampatsa A, Thompson JC, <i> et al.</i>: Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer. <i>Cancer Immunol Res.</i> 2019; <b>7</b>(6): 896–909. <a target=xrefwindow id=d12713e1460 href="http://www.ncbi.nlm.nih.gov/pubmed/31053597">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1463 href="https://doi.org/10.1158/2326-6066.CIR-18-0713">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1467 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6548666">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735695817">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d12713e1480 class=n-a></a>Kong Y, Zhu L, Schell TD, <i> et al.</i>: T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8<sub>+</sub> T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. <i>Clin Cancer Res.</i> 2016; <b>22</b>(12): 3057–66. <a target=xrefwindow id=d12713e1494 href="http://www.ncbi.nlm.nih.gov/pubmed/26763253">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1498 href="https://doi.org/10.1158/1078-0432.CCR-15-2626">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d12713e1507 class=n-a></a>Stanietsky N, Simic H, Arapovic J, <i> et al.</i>: The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(42): 17858–63. <a target=xrefwindow id=d12713e1518 href="http://www.ncbi.nlm.nih.gov/pubmed/19815499">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1521 href="https://doi.org/10.1073/pnas.0903474106">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1525 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2764881">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734049342"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1534 class=n-a></a>Solomon BL, Garrido-Laguna I: TIGIT: a novel immunotherapy target moving from bench to bedside. <i>Cancer Immunol Immunother.</i> 2018; <b>67</b>(11): 1659–67. <a target=xrefwindow id=d12713e1542 href="http://www.ncbi.nlm.nih.gov/pubmed/30232519">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1545 href="https://doi.org/10.1007/s00262-018-2246-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734049342">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d12713e1559 class=n-a></a>Bottino C, Castriconi R, Pende D, <i> et al.</i>: Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. <i>J Exp Med.</i> 2003; <b>198</b>(4): 557–67. <a target=xrefwindow id=d12713e1570 href="http://www.ncbi.nlm.nih.gov/pubmed/12913096">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1573 href="https://doi.org/10.1084/jem.20030788">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1577 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2194180">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733387154"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1586 class=n-a></a>Georgiev H, Ravens I, Papadogianni G, <i> et al.</i>: Coming of Age: CD96 Emerges as Modulator of Immune Responses. <i>Front Immunol.</i> 2018; <b>9</b>: 1072. <a target=xrefwindow id=d12713e1597 href="http://www.ncbi.nlm.nih.gov/pubmed/29868026">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1600 href="https://doi.org/10.3389/fimmu.2018.01072">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1604 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5966540">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733387154">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d12713e1617 class=n-a></a>El-Sherbiny YM, Meade JL, Holmes TD, <i> et al.</i>: The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. <i>Cancer Res.</i> 2007; <b>67</b>(18): 8444–9. <a target=xrefwindow id=d12713e1628 href="http://www.ncbi.nlm.nih.gov/pubmed/17875681">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1631 href="https://doi.org/10.1158/0008-5472.CAN-06-4230">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d12713e1640 class=n-a></a>Fuchs A, Cella M, Giurisato E, <i> et al.</i>: Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). <i>J Immunol.</i> 2004; <b>172</b>(7): 3994–8. <a target=xrefwindow id=d12713e1651 href="http://www.ncbi.nlm.nih.gov/pubmed/15034010">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1654 href="https://doi.org/10.4049/jimmunol.172.7.3994">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d12713e1663 class=n-a></a>Blake SJ, Dougall WC, Miles JJ, <i> et al.</i>: Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. <i>Clin Cancer Res.</i> 2016; <b>22</b>(21): 5183–8. <a target=xrefwindow id=d12713e1674 href="http://www.ncbi.nlm.nih.gov/pubmed/27620276">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1677 href="https://doi.org/10.1158/1078-0432.CCR-16-0933">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d12713e1686 class=n-a></a>McVicar DW, Burshtyn DN: Intracellular signaling by the killer immunoglobulin-like receptors and Ly49. <i>Sci STKE.</i> 2001; <b>2001</b>(75): re1. <a target=xrefwindow id=d12713e1694 href="http://www.ncbi.nlm.nih.gov/pubmed/11752646">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1697 href="https://doi.org/10.1126/stke.2001.75.re1">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735229578"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1707 class=n-a></a>Gorgisen G, Hapil FZ, Yilmaz O, <i> et al.</i>: Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer. <i>Genet Mol Biol.</i> 2019; <b>42</b>(1): 15–25. <a target=xrefwindow id=d12713e1718 href="http://www.ncbi.nlm.nih.gov/pubmed/30807634">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1721 href="https://doi.org/10.1590/1678-4685-GMB-2017-0307">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1725 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6428125">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735229578">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737700843"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1738 class=n-a></a>Vernieri C, Corti F, Nichetti F, <i> et al.</i>: Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Res.</i> 2020; <b>22</b>(1): 33. <a target=xrefwindow id=d12713e1749 href="http://www.ncbi.nlm.nih.gov/pubmed/32252811">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1752 href="https://doi.org/10.1186/s13058-020-01271-0">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1756 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7137211">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737700843">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737671294"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1769 class=n-a></a>Ortega MA, Fraile-Martínez O, Asúnsolo Á, <i> et al.</i>: Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. <i>J Oncol.</i> 2020; <b>2020</b>: 9258396. <a target=xrefwindow id=d12713e1780 href="http://www.ncbi.nlm.nih.gov/pubmed/32211045">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1783 href="https://doi.org/10.1155/2020/9258396">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1787 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7085392">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737671294">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737676680"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1800 class=n-a></a>Mollon LE, Anderson EJ, Dean JL, <i> et al.</i>: A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR<sub>+</sub>/HER2<sub>-</sub> Metastatic Breast Cancer. <i>Clin Breast Cancer.</i> 2019; pii: S1526-8209(19)30670-6. <a target=xrefwindow id=d12713e1814 href="http://www.ncbi.nlm.nih.gov/pubmed/32234362">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1818 href="https://doi.org/10.1016/j.clbc.2019.08.011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737676680">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737423260"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d12713e1831 class=n-a></a>Wang J, Li CD, Sun L: Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma. <i>Biomolecules.</i> 2020; <b>10</b>(2): pii: E301. <a target=xrefwindow id=d12713e1839 href="http://www.ncbi.nlm.nih.gov/pubmed/32075046">PubMed Abstract </a> | <a target=xrefwindow id=d12713e1842 href="https://doi.org/10.3390/biom10020301">Publisher Full Text </a> | <a target=xrefwindow id=d12713e1845 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7094213">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737423260">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-354/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-354/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Cancer Research Center of Marseille, INSERM U1068, CNRS U7258, Aix Marseille Universit&eacute;, Institut Paoli &ndash; Calmettes, Marseille, France<br/> <p> <div class=margin-bottom> Laurent Gorvel <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Daniel Olive <br/> <span>Roles: </span> Funding Acquisition, Resources, Supervision, Validation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-354/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 13 May 2020, 9:354 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.22877.1">https://doi.org/10.12688/f1000research.22877.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Gorvel L and Olive D. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=25255 data-id=22877 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22877.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-354/v1/pdf?article_uuid=0858c6f9-8000-4737-bc9f-3840373f77a6" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.22877.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Gorvel L and Olive D. Targeting the “PVR–TIGIT axis” with immune checkpoint therapies [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):354 (<a href="https://doi.org/10.12688/f1000research.22877.1" target=_blank>https://doi.org/10.12688/f1000research.22877.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=22877 id=mobile-track-article-signin-22877 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22877?target=/articles/9-354/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=25255 /> <input name=articleId type=hidden value=22877 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Peter Steinberger</strong>, Division of Immune Receptors and T cell Activation, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Eyad Elkord</strong>, Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Qatar; Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-354/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-354/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=67318-63205></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=67317-63206></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-354/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>13 May 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Peter Steinberger</strong>, Division of Immune Receptors and T cell Activation, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Eyad Elkord</strong>, Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Qatar; Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-354/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-354/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Targeting the \u201CPVR\u2013TIGIT axis\u201D...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-354/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-354/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-354/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Gorvel L and Olive D');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-354/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-354",
            templates : {
                twitter : "Targeting the \u201CPVR\u2013TIGIT axis\u201D with immune checkpoint.... Gorvel L and Olive D, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-354/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Targeting the \u201CPVR\u2013TIGIT axis\u201D with immune checkpoint therapies", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Targeting the \u201CPVR\u2013TIGIT axis\u201D with immune checkpoint therapies", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/22877/25255")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "25255");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "63205": 1,
                           "63206": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "855a141b-5dc9-410f-9b3c-079d00b0e5ab";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-354.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-354.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-354.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-354.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-354.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>